Key result
Plasma IK17-scFv expression cuts en face atherosclerosis ~46% in hypercholesterolemic mice.
Why the study?
The in vivo importance of scavenger receptor-mediated uptake of oxidized LDL in atherogenesis and the efficacy of oxidation-specific antibodies to inhibit atherosclerosis progression were uncertain.
Does human oxidation-specific antibody IK17 reduce atherosclerosis progression in cholesterol-fed LDLR−/− and LDLR−/−/Rag−/− mice?
Does human oxidation-specific antibody IK17 reduce atherosclerosis progression in cholesterol-fed LDLR−/− and LDLR−/−/Rag−/− mice?
Answers are grounded in this paper and cite their sources.
Oxidation-specific antibodies targeting oxidized LDL reduce atherosclerosis progression in mouse models, suggesting a potential therapeutic pathway for cardiovascular disease.
Objectives We sought to assess the in vivo importance of scavenger receptor (SR)-mediated uptake of oxidized low density lipoprotein (OxLDL) in atherogenesis and test the efficacy of human antibody IK17-Fab or IK17 single chain Fv fragment (IK17-scFv), which lack immunological properties of intact antibodies other than the ability to inhibit uptake of OxLDL by macrophages, to inhibit atherosclerosis. Background The unregulated uptake of OxLDL by macrophage SR contributes to foam cell formation but the importance of this pathway in vivo is uncertain. Methods Cholesterol-fed LDLR−/− mice were treated with intraperitoneal infusion of human IK17-Fab (2.5mg/kg) 3 times/week for 14 weeks. Because these mice developed anti-human antibodies, LDLR−/−/Rag−/− mice (lacking ability to make immunoglobulins due to loss of T and B cell function) were treated with an adenoviral vector encoding Adv-IK17-scFv or control adenoviral-enhanced green fluorescent protein (adv-EGFP) vector intravenously every 2 weeks for 16 weeks. Results In LDLR−/− mice, infusion of IK17-Fab was able to sustain IK17 plasma levels for the first 8 weeks, but these diminished afterwards due to increasing murine anti-IK17 antibody titers. Despite this, after 14 weeks a 29% decrease in en face atherosclerosis was noted compared to PBS treated mice. In LDLR−/−/Rag−/− mice, sustained levels of plasma IK17-scFv was achieved by Adv-IK17-scFv mediated hepatic expression, which led to a 46% reduction (P<0.001) in en face atherosclerosis compared to adv-EGFP. Importantly, peritoneal macrophages isolated from Adv-IK17-scFv treated mice had decreased lipid accumulation compared to Adv-EGFP treated mice. Conclusion These data support an important role for SR-mediated uptake of OxLDL in the pathogenesis of atherosclerosis and demonstrate that oxidation-specific antibodies reduce the progression of atherosclerosis suggesting their potential in treating cardiovascular disease in humans.
No takes yet. Share an insight, caveat, or question.
Tsimikas et al. (2011) studied Atherosclerosis. Human antibody IK17-Fab or IK17-scFv vs. PBS or control adenoviral-enhanced green fluorescent protein (adv-EGFP) vector was evaluated on en face atherosclerosis (46% reduction, p=<0.001). In LDLR-/-/Rag-/- mice, sustained levels of plasma IK17-scFv led to a 46% reduction in en face atherosclerosis compared to adv-EGFP.
Synapse has enriched 10 related papers. Consider them for comparative context: